In the clinic, combination of bevacizumab, a humanized monoclonal antibody targeting VEGF, with ipilimumab (anti-CTLA-4) also demonstrated favorable therapeutic outcomes in patients with melanoma compared to ipilimumab treatment alone [109]. The gene discussed is CTLA4; the disease is melanoma.